 IBB the iShares Biotechnology ETF has already recovered about 30 over the past five months but Jefferies Michael Yee is convinced it still has more room to the upside. Yees bull case for the biotech stock Yee sees several catalysts that could potentially push these stocks further up in the coming months. 